Company intelligence / Profile preview

Aronnax

United States

Ownership: Private
Development stage: Other

Overview

Aronnax is providing IND-enabling toxicology and dose-finding services for Hoth Therapeutics’ antisense oligonucleotide drug candidate HT-KIT, which targets the proto-oncogene cKIT; the candidate has shown promising preclinical efficacy in reducing KIT receptor expression and killing KIT-dependent mast cells

Therapeutic areas: Oncology
Modalities: Antisense oligonucleotide
Industry: Contract Research Organization

Partnerships

Hoth Therapeutics

Beyond the preview

Go deeper on Aronnax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aronnax.

Explore the full profile